BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 29516978)

  • 1. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
    Li F; Ren Y; Wang Z
    J Cancer Res Ther; 2018 Jan; 14(1):150-154. PubMed ID: 29516978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
    Zhou T; Xu D; Tang B; Ren Y; Han Y; Liang G; Wang J; Wang L
    Anticancer Drugs; 2018 Oct; 29(9):904-910. PubMed ID: 30085937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
    Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
    Muenst S; Schaerli AR; Gao F; Däster S; Trella E; Droeser RA; Muraro MG; Zajac P; Zanetti R; Gillanders WE; Weber WP; Soysal SD
    Breast Cancer Res Treat; 2014 Jul; 146(1):15-24. PubMed ID: 24842267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.
    Lou J; Zhou Y; Huang J; Qian X
    Open Med (Wars); 2017; 12():288-292. PubMed ID: 28894845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
    Erol T; İmamoğlu NE; Aydin B; Taşkiran ZE; Esendağli G; Kösemehmetoğlu K; Baykal A
    Medicine (Baltimore); 2019 Aug; 98(33):e16773. PubMed ID: 31415379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
    Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
    Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
    Lafuente-Sanchis A; Zúñiga Á; Estors M; Martínez-Hernández NJ; Cremades A; Cuenca M; Galbis JM
    Clin Lung Cancer; 2017 Mar; 18(2):e109-e116. PubMed ID: 27816393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    Kim HM; Lee J; Koo JS
    BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer.
    Pranoto AS; Haryasena H; Prihantono P; Rahman S; Sampepajung D; Indra I; Syamsu SA; Sampepajung E; Nelwan BJ; Faruk M
    Breast Dis; 2021; 40(S1):S71-S76. PubMed ID: 34057120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer.
    Zhang WT; Zhu GL; Xu WQ; Zhang W; Wang HZ; Wang YB; Li YX
    Diagn Pathol; 2022 Jul; 17(1):61. PubMed ID: 35842661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
    Hirakata T; Fujii T; Kurozumi S; Katayama A; Honda C; Yanai K; Tokuda S; Nakazawa Y; Obayashi S; Yajima R; Kaira K; Oyama T; Shirabe K
    Breast Cancer Res Treat; 2020 Jun; 181(2):331-338. PubMed ID: 32253685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
    Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
    Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
    Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
    Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
    Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
    BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.